Saldaña Shannon N, Keeshin Brooks R, Wehry Anna M, Blom Thomas J, Sorter Michael T, DelBello Melissa P, Strawn Jeffrey R
Department of Pharmacy, Intermountain Primary Children's Hospital, Salt Lake City, Utah; Division of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Pharmacotherapy. 2014 Aug;34(8):836-44. doi: 10.1002/phar.1453. Epub 2014 Jul 3.
Antipsychotic polypharmacy-the use of more than one antipsychotic concomitantly-has increased in children and adolescents and may be associated with increased adverse effects, nonadherence, and greater costs. Thus, we sought to examine the demographic and clinical characteristics of psychiatrically hospitalized children and adolescents who were prescribed antipsychotic polypharmacy and to identify predictors of this prescribing pattern.
Retrospective medical record review.
The inpatient psychiatric unit of a large, acute care, urban children's hospital.
One thousand four hundred twenty-seven children and adolescents who were consecutively admitted and discharged between September 2010 and May 2011.
At discharge, 840 (58.9%) of the 1427 patients were prescribed one or more antipsychotics, and 99.3% of these received second-generation antipsychotics. Of these 840 patients, 724 (86.2%) were treated with antipsychotic monotherapy, and 116 (13.8%) were treated with antipsychotic polypharmacy. Positive correlations with antipsychotic polypharmacy were observed for placement or custody outside the biological family; a greater number of previous psychiatric admissions; longer hospitalizations; admission for violence/aggression or psychosis; and intellectual disability, psychotic, disruptive behavior, or developmental disorder diagnoses. Negative correlations with antipsychotic polypharmacy included admission for suicidal ideation/attempt or depression, and mood disorder diagnoses. Significant predictors of antipsychotic polypharmacy included admission for violence or aggression (odds ratio [OR] 2.76 [95% confidence interval (CI) 1.36-5.61]), greater number of previous admissions (OR 1.21 [95% CI 1.10-1.33]), and longer hospitalizations (OR 1.08 [95% CI 1.04-1.12]). In addition, diagnoses of intellectual disability (OR 2.62 [95% CI 1.52-4.52]), psychotic disorders (OR 5.60 [95% CI 2.29-13.68]), and developmental disorders (OR 3.18 [95% CI 1.78-5.65]) were predictors of antipsychotic polypharmacy.
Certain youth may have a higher likelihood of being prescribed antipsychotic polypharmacy, which should prompt careful consideration of medication treatment options during inpatient hospitalization. Future examinations of the rationale for combining antipsychotics, along with the long-term safety, tolerability, and cost effectiveness of these therapies, in youth are urgently needed.
儿童和青少年中抗精神病药物联合使用(同时使用一种以上抗精神病药物)的情况有所增加,这可能与不良反应增加、治疗依从性差及成本增加有关。因此,我们试图研究接受抗精神病药物联合治疗的住院精神科儿童和青少年的人口统计学和临床特征,并确定这种用药模式的预测因素。
回顾性病历审查。
一家大型城市急症儿童医院的住院精神科病房。
2010年9月至2011年5月期间连续入院和出院的1427名儿童和青少年。
出院时,1427名患者中有840名(58.9%)被开具了一种或多种抗精神病药物,其中99.3%接受了第二代抗精神病药物治疗。在这840名患者中,724名(86.2%)接受了抗精神病药物单一疗法治疗,116名(13.8%)接受了抗精神病药物联合治疗。抗精神病药物联合治疗与以下因素呈正相关:非原生家庭安置或监护;既往精神科住院次数较多;住院时间较长;因暴力/攻击行为或精神病入院;以及智力残疾、精神病、破坏性行为或发育障碍诊断。抗精神病药物联合治疗的负相关因素包括因自杀观念/企图或抑郁入院,以及情绪障碍诊断。抗精神病药物联合治疗的显著预测因素包括因暴力或攻击行为入院(比值比[OR]2.76[95%置信区间(CI)1.36 - 5.61])、既往住院次数较多(OR 1.21[95%CI 1.10 - 1.33])和住院时间较长(OR 1.08[95%CI 1.04 - 1.12])。此外,智力残疾诊断(OR 2.62[95%CI 1.52 - 4.52])、精神障碍诊断(OR 5.60[95%CI 2.29 - 13.68])和发育障碍诊断(OR 3.18[95%CI 1.78 - 5.65])是抗精神病药物联合治疗的预测因素。
某些青少年接受抗精神病药物联合治疗的可能性可能更高,这应促使在住院治疗期间仔细考虑药物治疗方案。迫切需要对青少年联合使用抗精神病药物的理由以及这些疗法的长期安全性、耐受性和成本效益进行进一步研究。